Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Total Current Liabilities (2018 - 2025)

Neurogene's Total Current Liabilities history spans 6 years, with the latest figure at $16.4 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 8.27% year-over-year to $16.4 million; the TTM value through Dec 2025 reached $16.4 million, up 8.27%, while the annual FY2025 figure was $16.4 million, 8.27% up from the prior year.
  • Total Current Liabilities reached $16.4 million in Q4 2025 per NGNE's latest filing, up from $14.7 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $23.0 million in Q4 2023 to a low of $4.9 million in Q2 2023.
  • Average Total Current Liabilities over 3 years is $13.1 million, with a median of $14.4 million recorded in 2025.
  • The largest YoY upside for Total Current Liabilities was 203.15% in 2024 against a maximum downside of 34.02% in 2024.
  • A 3-year view of Total Current Liabilities shows it stood at $23.0 million in 2023, then plummeted by 34.02% to $15.2 million in 2024, then grew by 8.27% to $16.4 million in 2025.
  • Per Business Quant, the three most recent readings for NGNE's Total Current Liabilities are $16.4 million (Q4 2025), $14.7 million (Q3 2025), and $15.4 million (Q2 2025).